Africa: Single-Dose Treatment for Sleeping Sickness Receives Approval: [Drugs for Neglected Diseases initiative (DNDi)] Kinshasa / Paris / Geneva / Amsterdam -- · Recommendation based on Phase II/III study demonstrating up to 96 per cent success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sickness· The therapy, given as a single dose of three… http://newsfeed.facilit8.network/TRC0k5 #SleepingSickness #TBDisease #PublicHealth #GlobalHealth #WHO